Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma : RENOTORCH, a randomized, open-label, phase III study
Copyright © 2023 X. Yan, M. Ye, Q. Zou, P. Chen, Z. He, B. Wu, D. He, C. He, X. Xue, Z. Ji, H. Chen, S. Zhang, Y. Liu, X. Zhang, C. Fu, D. Xu, M. Qiu, J. Lv, J. Huang, X. Ren, Y. Cheng, W. Qin, X. Zhang, F. Zhou, L. Ma, J. Guo, D. Ding, S. Wei, Y. He, H. Guo, B. Shi, L. Liu, F. Liu, Z. Hu, X. Jin, L. Yang, S. Zhu, J. Liu, Y. Huang, T. Xu, B. Liu, T. Sun, Z. Wang, H. Jiang, D. Yu, A. Zhou, J. Jiang, G. Luan, C. Jin, J. Xu, J. Hu, Y. H, Jun, W. Zhai, X. Sheng, Shanghai Junshi Biosciences Co. LTD, Shanghai Junshi Biosciences Co. LTD., a. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab plus axitinib versus sunitinib for the first-line treatment of patients with intermediate-/poor-risk advanced RCC.
PATIENTS AND METHODS: Patients with intermediate-/poor-risk unresectable or metastatic RCC were randomized in a ratio of 1 : 1 to receive toripalimab (240 mg intravenously once every 3 weeks) plus axitinib (5 mg orally twice daily) or sunitinib [50 mg orally once daily for 4 weeks (6-week cycle) or 2 weeks (3-week cycle)]. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC). The secondary endpoints were investigator-assessed PFS, overall response rate (ORR), overall survival (OS), and safety.
RESULTS: A total of 421 patients were randomized to receive toripalimab plus axitinib (n = 210) or sunitinib (n = 211). With a median follow-up of 14.6 months, toripalimab plus axitinib significantly reduced the risk of disease progression or death by 35% compared with sunitinib as assessed by an IRC [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86; P = 0.0028]. The median PFS was 18.0 months in the toripalimab-axitinib group, whereas it was 9.8 months in the sunitinib group. The IRC-assessed ORR was significantly higher in the toripalimab-axitinib group compared with the sunitinib group (56.7% versus 30.8%; P < 0.0001). An OS trend favoring toripalimab plus axitinib was also observed (HR 0.61, 95% CI 0.40-0.92). Treatment-related grade ≥3 adverse events occurred in 61.5% of patients in the toripalimab-axitinib group and 58.6% of patients in the sunitinib group.
CONCLUSION: In patients with previously untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib provided significantly longer PFS and higher ORR than sunitinib and had a manageable safety profile TRIAL REGISTRATION: ClinicalTrials.gov NCT04394975.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 35(2024), 2 vom: 15. Feb., Seite 190-199 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yan, X Q [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.02.2024 Date Revised 22.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT04394975 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2023.09.3108 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363643079 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363643079 | ||
| 003 | DE-627 | ||
| 005 | 20240229143800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2023.09.3108 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM363643079 | ||
| 035 | |a (NLM)37872020 | ||
| 035 | |a (PII)S0923-7534(23)04003-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yan, X Q |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma |b RENOTORCH, a randomized, open-label, phase III study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2024 | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04394975 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 X. Yan, M. Ye, Q. Zou, P. Chen, Z. He, B. Wu, D. He, C. He, X. Xue, Z. Ji, H. Chen, S. Zhang, Y. Liu, X. Zhang, C. Fu, D. Xu, M. Qiu, J. Lv, J. Huang, X. Ren, Y. Cheng, W. Qin, X. Zhang, F. Zhou, L. Ma, J. Guo, D. Ding, S. Wei, Y. He, H. Guo, B. Shi, L. Liu, F. Liu, Z. Hu, X. Jin, L. Yang, S. Zhu, J. Liu, Y. Huang, T. Xu, B. Liu, T. Sun, Z. Wang, H. Jiang, D. Yu, A. Zhou, J. Jiang, G. Luan, C. Jin, J. Xu, J. Hu, Y. H, Jun, W. Zhai, X. Sheng, Shanghai Junshi Biosciences Co. LTD, Shanghai Junshi Biosciences Co. LTD., a. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab plus axitinib versus sunitinib for the first-line treatment of patients with intermediate-/poor-risk advanced RCC | ||
| 520 | |a PATIENTS AND METHODS: Patients with intermediate-/poor-risk unresectable or metastatic RCC were randomized in a ratio of 1 : 1 to receive toripalimab (240 mg intravenously once every 3 weeks) plus axitinib (5 mg orally twice daily) or sunitinib [50 mg orally once daily for 4 weeks (6-week cycle) or 2 weeks (3-week cycle)]. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC). The secondary endpoints were investigator-assessed PFS, overall response rate (ORR), overall survival (OS), and safety | ||
| 520 | |a RESULTS: A total of 421 patients were randomized to receive toripalimab plus axitinib (n = 210) or sunitinib (n = 211). With a median follow-up of 14.6 months, toripalimab plus axitinib significantly reduced the risk of disease progression or death by 35% compared with sunitinib as assessed by an IRC [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86; P = 0.0028]. The median PFS was 18.0 months in the toripalimab-axitinib group, whereas it was 9.8 months in the sunitinib group. The IRC-assessed ORR was significantly higher in the toripalimab-axitinib group compared with the sunitinib group (56.7% versus 30.8%; P < 0.0001). An OS trend favoring toripalimab plus axitinib was also observed (HR 0.61, 95% CI 0.40-0.92). Treatment-related grade ≥3 adverse events occurred in 61.5% of patients in the toripalimab-axitinib group and 58.6% of patients in the sunitinib group | ||
| 520 | |a CONCLUSION: In patients with previously untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib provided significantly longer PFS and higher ORR than sunitinib and had a manageable safety profile TRIAL REGISTRATION: ClinicalTrials.gov NCT04394975 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a advanced renal cell carcinoma | |
| 650 | 4 | |a axitinib | |
| 650 | 4 | |a progression-free survival | |
| 650 | 4 | |a sunitinib | |
| 650 | 4 | |a toripalimab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Axitinib |2 NLM | |
| 650 | 7 | |a C9LVQ0YUXG |2 NLM | |
| 650 | 7 | |a Sunitinib |2 NLM | |
| 650 | 7 | |a V99T50803M |2 NLM | |
| 650 | 7 | |a toripalimab |2 NLM | |
| 650 | 7 | |a 8JXN261VVA |2 NLM | |
| 700 | 1 | |a Ye, M J |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Q |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, P |e verfasserin |4 aut | |
| 700 | 1 | |a He, Z S |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, B |e verfasserin |4 aut | |
| 700 | 1 | |a He, D L |e verfasserin |4 aut | |
| 700 | 1 | |a He, C H |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, X Y |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Z G |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, H |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, S |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Y P |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, X D |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, C |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, D F |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, M X |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, J J |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, J |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, X B |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, W J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, X |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, F J |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, L L |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, D G |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, S Z |e verfasserin |4 aut | |
| 700 | 1 | |a He, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, H Q |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, B K |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, L |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, F |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Z Q |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, X M |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, L |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, S X |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, J H |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, T |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, B |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, T |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Z J |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, H W |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, D X |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, A P |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, J |e verfasserin |4 aut | |
| 700 | 1 | |a Luan, G D |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, C L |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, J |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, J X |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Y R |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, W |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, X N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 35(2024), 2 vom: 15. Feb., Seite 190-199 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:2 |g day:15 |g month:02 |g pages:190-199 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2023.09.3108 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2024 |e 2 |b 15 |c 02 |h 190-199 | ||